150 related articles for article (PubMed ID: 38423666)
21. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.
Konduri SD; Medisetty R; Liu W; Kaipparettu BA; Srivastava P; Brauch H; Fritz P; Swetzig WM; Gardner AE; Khan SA; Das GM
Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15081-6. PubMed ID: 20696891
[TBL] [Abstract][Full Text] [Related]
22. Hispolon inhibits the growth of estrogen receptor positive human breast cancer cells through modulation of estrogen receptor alpha.
Jang EH; Jang SY; Cho IH; Hong D; Jung B; Park MJ; Kim JH
Biochem Biophys Res Commun; 2015 Aug; 463(4):917-22. PubMed ID: 26056942
[TBL] [Abstract][Full Text] [Related]
23. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; Medema RH; Hartman J; Lykkesfeldt AE; Lam EW
Oncogene; 2010 May; 29(20):2983-95. PubMed ID: 20208560
[TBL] [Abstract][Full Text] [Related]
24. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
[TBL] [Abstract][Full Text] [Related]
25. BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells.
Nathan S; Ma Y; Tomita YA; De Oliveira E; Brown ML; Rosen EM
Breast Cancer Res Treat; 2017 Dec; 166(3):681-693. PubMed ID: 28808806
[TBL] [Abstract][Full Text] [Related]
26. Huaier aqueous extract suppresses human breast cancer cell proliferation through inhibition of estrogen receptor α signaling.
Wang X; Zhang N; Huo Q; Sun M; Lv S; Yang Q
Int J Oncol; 2013 Jul; 43(1):321-8. PubMed ID: 23686317
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer.
Rosenblatt AE; Garcia MI; Lyons L; Xie Y; Maiorino C; Désiré L; Slingerland J; Burnstein KL
Endocr Relat Cancer; 2011 Apr; 18(2):207-19. PubMed ID: 21118977
[TBL] [Abstract][Full Text] [Related]
28. Bisphenol AF-induced endogenous transcription is mediated by ERα and ERK1/2 activation in human breast cancer cells.
Li M; Guo J; Gao W; Yu J; Han X; Zhang J; Shao B
PLoS One; 2014; 9(4):e94725. PubMed ID: 24727858
[TBL] [Abstract][Full Text] [Related]
29. Tumor-suppressive effects of psoriasin (S100A7) are mediated through the β-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells.
Deol YS; Nasser MW; Yu L; Zou X; Ganju RK
J Biol Chem; 2011 Dec; 286(52):44845-54. PubMed ID: 22016394
[TBL] [Abstract][Full Text] [Related]
30. Furanodienone inhibits cell proliferation and survival by suppressing ERα signaling in human breast cancer MCF-7 cells.
Li YW; Zhu GY; Shen XL; Chu JH; Yu ZL; Fong WF
J Cell Biochem; 2011 Jan; 112(1):217-24. PubMed ID: 21069738
[TBL] [Abstract][Full Text] [Related]
31. Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.
Karam M; Bièche I; Legay C; Vacher S; Auclair C; Ricort JM
J Cell Mol Med; 2014 Dec; 18(12):2536-52. PubMed ID: 25287328
[TBL] [Abstract][Full Text] [Related]
32. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.
Lewis-Wambi JS; Kim H; Curpan R; Grigg R; Sarker MA; Jordan VC
Mol Pharmacol; 2011 Oct; 80(4):610-20. PubMed ID: 21737572
[TBL] [Abstract][Full Text] [Related]
33. Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha.
Lin W; Huang J; Liao X; Yuan Z; Feng S; Xie Y; Ma W
Pharmacol Res; 2016 Sep; 111():849-858. PubMed ID: 27491559
[TBL] [Abstract][Full Text] [Related]
34. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
35. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
[TBL] [Abstract][Full Text] [Related]
36. A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}.
Kretzer NM; Cherian MT; Mao C; Aninye IO; Reynolds PD; Schiff R; Hergenrother PJ; Nordeen SK; Wilson EM; Shapiro DJ
J Biol Chem; 2010 Dec; 285(53):41863-73. PubMed ID: 21041310
[TBL] [Abstract][Full Text] [Related]
37. Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer.
Andruska N; Zheng X; Yang X; Helferich WG; Shapiro DJ
Oncogene; 2015 Jul; 34(29):3760-9. PubMed ID: 25263449
[TBL] [Abstract][Full Text] [Related]
38. RUNX1T1, a potential prognostic marker in breast cancer, is co-ordinately expressed with ERα, and regulated by estrogen receptor signalling in breast cancer cells.
Saikia S; Pal U; Kalita DJ; Rai AK; Sarma A; Kataki AC; Limaye AM
Mol Biol Rep; 2021 Jul; 48(7):5399-5409. PubMed ID: 34264479
[TBL] [Abstract][Full Text] [Related]
39. Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor.
Ellison-Zelski SJ; Alarid ET
Mol Cancer; 2010 Sep; 9():263. PubMed ID: 20920219
[TBL] [Abstract][Full Text] [Related]
40. Shugan Liangxue Decoction () Down-Regulates Estrogen Receptor α Expression in Breast Cancer Cells.
Zhou N; Han SY; Chen YZ; Zhou F; Zheng WX; Li PP
Chin J Integr Med; 2018 Jul; 24(7):518-524. PubMed ID: 26740221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
